These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 20525293)

  • 1. Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer.
    Kitayama J; Yasuda K; Kawai K; Sunami E; Nagawa H
    Radiat Oncol; 2010 Jun; 5():47. PubMed ID: 20525293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer.
    Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Miyakita H; Ogimi T; Nagase H
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1077-1085. PubMed ID: 28417167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer.
    Li A; He K; Guo D; Liu C; Wang D; Mu X; Yu J
    Future Oncol; 2019 Oct; 15(28):3233-3242. PubMed ID: 31373223
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and short-term outcomes of preoperative chemoradiotherapy with intermittent oral tegafur-uracil plus leucovorin in Japanese rectal cancer patients: a single center experience retrospective analysis.
    Nakagawa R; Inoue Y; Ohki T; Kaneko Y; Maeda F; Yamamoto M
    World J Surg Oncol; 2017 May; 15(1):112. PubMed ID: 28566093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery.
    Toiyama Y; Inoue Y; Saigusa S; Kawamura M; Kawamoto A; Okugawa Y; Hiro J; Tanaka K; Mohri Y; Kusunoki M
    Anticancer Res; 2013 Nov; 33(11):5065-74. PubMed ID: 24222151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Predictors of Recurrence in Patients with Lower Rectal Cancer Undergoing Neoadjuvant Chemotherapy: A Direct Comparison of Short-Course and Long-Course Chemoradiotherapy.
    Yamamoto A; Toiyama Y; Okugawa Y; Saigusa S; Ide S; Fujikawa H; Hiro J; Yasuda H; Yoshiyama S; Ohi M; Araki T; Kusunoki M
    Oncology; 2019; 96(2):70-78. PubMed ID: 30227430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcatheter rectal arterial chemoembolization with oxaliplatin plus S-1 concurrent chemoradiotherapy can improve the pathological remission rate in locally advanced rectal cancer: a comparative study.
    Yang B; Shan J; Feng Y; Dai N; Li M; Chen C; He S; Wang G; Xiao H; Li C; Wang D
    Radiat Oncol; 2020 May; 15(1):94. PubMed ID: 32375814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory blood data have a significant impact on tumor response and outcome in preoperative chemoradiotherapy for advanced rectal cancer.
    Yasuda K; Sunami E; Kawai K; Nagawa H; Kitayama J
    J Gastrointest Cancer; 2012 Jun; 43(2):236-43. PubMed ID: 21365477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer.
    Jung M; Shin SJ; Koom WS; Jung I; Keum KC; Hur H; Min BS; Baik SH; Kim NK; Kim H; Lim JS; Hong SP; Kim TI; Roh JK; Park YS; Ahn JB
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1015-22. PubMed ID: 26581140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
    Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
    Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of pathological response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer.
    Tomono A; Yamashita K; Kanemitsu K; Sumi Y; Yamamoto M; Kanaji S; Imanishi T; Nakamura T; Suzuki S; Tanaka K; Kakeji Y
    Int J Clin Oncol; 2016 Apr; 21(2):344-349. PubMed ID: 26338272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting Pathological Complete Regression with Haematological Markers During Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.
    Lee JH; Song C; Kang SB; Lee HS; Lee KW; Kim JS
    Anticancer Res; 2018 Dec; 38(12):6905-6910. PubMed ID: 30504408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Pathological Complete Response Using Endoscopic Findings and Outcomes of Patients Who Underwent Watchful Waiting After Chemoradiotherapy for Rectal Cancer.
    Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Morikawa T; Fukayama M; Watanabe T
    Dis Colon Rectum; 2017 Apr; 60(4):368-375. PubMed ID: 28267003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets.
    Tada N; Kawai K; Tsuno NH; Ishihara S; Yamaguchi H; Sunami E; Kitayama J; Oba K; Watanabe T
    World J Surg Oncol; 2015 Feb; 13():30. PubMed ID: 25890185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery.
    Yang KL; Yang SH; Liang WY; Kuo YJ; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC; Chu LS; Wang LW
    Radiat Oncol; 2013 Mar; 8():43. PubMed ID: 23452434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of anal sphincter preservation rate according to tumor level and neoadjuvant chemoradiotherapy in rectal cancer patients.
    Baik SH; Kim NK; Lee KY; Sohn SK; Cho CH
    J Gastrointest Surg; 2008 Jan; 12(1):176-82. PubMed ID: 17694418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustaining Blood Lymphocyte Count during Preoperative Chemoradiotherapy as a Predictive Marker for Pathologic Complete Response in Locally Advanced Rectal Cancer.
    Heo J; Chun M; Noh OK; Oh YT; Suh KW; Park JE; Cho O
    Cancer Res Treat; 2016 Jan; 48(1):232-9. PubMed ID: 25779365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer.
    Kitayama J; Yasuda K; Kawai K; Sunami E; Nagawa H
    BMC Cancer; 2011 Feb; 11():64. PubMed ID: 21306650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
    Nakamura T; Yamashita K; Sato T; Ema A; Naito M; Watanabe M
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):547-55. PubMed ID: 24929164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.